The antibody was purified by affinity chromatography and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.
CXCL5, also known as ENA-78, is a 11.9 kD chemokine and belongs to the intercrine alpha, CXC chemokine family. It is expressed by monocytes and eosinophils in response to IL-1 and TNFα. CXCL5 can interact with CXCR2 and activate neutrophils and induce their migration. In vitro neutrophil chemotactic activity of CXCL5 is three fold higher. IFNγ suppresses expression of CXCL5. NFκB alone is sufficient to induce CXCL5 in contrast to IL-8, which requires both NFκB and C/EBP. Two forms are produced by N terminal proteolytic cleavage, ENA78 (8-78) and ENA 78 (9-78), and these isoforms exhibit higher chemotactic activity. Increased intra-hepatic levels of CXCL5 have been reported in patients with chronic liver disease.